Two-Dimensional-PAGE Coupled with nLC-MS/MS-Based Identification of Differentially Expressed Proteins and Tumorigenic

Madhuri Jayathirtha1, Taniya Jayaweera1, Danielle Whitham1

  • 1Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, 8 Clarkson Avenue, Potsdam, NY 13699, USA.

PubMed

Insights

The human jumping translocation breakpoint (hJTB) protein may serve as a breast cancer (BC) biomarker and therapeutic target. Silencing hJTB in MCF7 cells promoted pro-tumorigenic pathways, indicating its tumor-suppressive role.

Area of Science:

  • Proteomics
  • Cancer Biology
  • Bioinformatics

Background:

  • Advances in bioinformatics and molecular profiling enable identification of cancer-associated genes and pathways.
  • The human jumping translocation breakpoint (hJTB) protein is proposed as a potential breast cancer (BC) biomarker and therapeutic target.

Purpose of the Study:

  • To identify differentially expressed proteins (DEPs), carcinogenic pathways, and biological processes linked to JTB silencing in MCF7 cells.
  • To further characterize the tumor-suppressive function of hJTB in breast cancer.

Main Methods:

  • Proteomic analysis using 2D-PAGE and nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS).
  • Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses for functional annotation of DEPs.
  • Utilized MCF7 breast cancer cell line with downregulated JTB expression.

Main Results:

  • JTB silencing led to the identification of numerous DEPs.
  • These DEPs are implicated in pro-tumorigenic pathways including EMT, MAPK, PI3K/AKT, Wnt/β-catenin, mTOR, C-MYC, NF-κB, IFN responses, UPR, and glycolysis.
  • The identified pathways support cancer hallmarks like growth, invasion, metastasis, stemness, and metabolic reprogramming.

Conclusions:

  • JTB silencing enhances the neoplastic phenotype and behavior in MCF7 breast cancer cells.
  • hJTB protein demonstrates tumor-suppressive functions.
  • The findings support hJTB as a potential biomarker and therapeutic target for breast cancer.

Related Concept Videos